Inviragen has received two grants from the US Government to continue ongoing programmes aimed at developing vaccines against dengue and chikungunya viruses.
The two grants totalling $488,958 have been awarded by the US Government’s Qualifying Therapeutic Discovery Project Program.
Inviragen is currently conducing two phase I human clinical trials of its dengue vaccine, DENVax, and its investigational chikungunya vaccine is undergoing preclinical trials.
Inviragen CEO Dr Dan Stinchcomb said that the Department of Health and Human Services has recognised the potential public health impact of Inviragen’s dengue and chikungunya vaccines.
“The funds will permit Inviragen to accelerate our clinical and preclinical vaccine studies,” Stinchcomb added.
